So far in this book we have considered the use of aphrodisiacs from about 3000 BC to the present day. In this final chapter we shall be examining the possible aphrodisiacs of the future. It is most unlikely that a pharmaceutical company would undertake the necessary research and development required to produce a drug which could be marketed as an aphrodisiac. It has been estimated that each successful new drug introduced on to the market represents at least seven years’ development work and an investment of between ten and twenty million pounds. Add to this the problems of assessing aphrodisiac activity, and the need to convince the Committee on the Safety of Medicines that there is an ethical clinical role for such a drug, and the likely return on the investment becomes a doubtful economic proposition. On the other hand, there is always the possibility that a newly introduced drug turns out to have significant aphrodisiac side-effects. It is very much easier to obtain approval for a novel use of an existing drug which has already undergone all the necessary toxicological and clinical screening than to satisfy the safety requirements for a completely new compound.
KeywordsSexual Arousal Physical Attractiveness Sexual Attraction Vaginal Secretion Musk Deer
Unable to display preview. Download preview PDF.
- King, J. (1983) `Have the Scents to Relax’, World Medicine 19, 29Google Scholar
- 2.Waltman, R. et al. (1973) Lancet ii 496Google Scholar
- 4.Perfumery (Creative Leisure Series, International Publications Service, New York, 1975)Google Scholar
- 6.The Role of Pleasure in Behaviour,R.G. Heath, ed. (Harper & Row, London, 1964), p. 219Google Scholar